About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.

Muco-ciliary Cleansing of Lungs in COPD With and Without a Salt Particle Inhaler

Clinicaltrials.gov identifier NCT03927365

Recruitment Status Recruiting

First Posted April 25, 2019

Last update posted February 21, 2020

Study Description

Brief summary:

Cross-over trial of the effect of a salt particle inhaler on pulmonary muco-ciliary cleansing in COPD patients as measured by lung scintigraphy.

  • Condition or Disease:COPD
    Copd Bronchitis
  • Intervention/Treatment: Device: Inhalation from a salt particle inhaler with or without content
  • Phase: N/A
Detailed Description

Stable COPD patients will be examined twice with minimum two, maximum 14 days interval. In randomized order the patients will inhale from a salt particle inhaler with (active) or without (placebo) content.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 35 participants
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Intervention Model Description: Participants cross over from active to placebo or vice versa in random order
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: Muco-ciliary Cleansing of Lungs in COPD With and Without a Salt Particle Inhaler
  • Actual Study Start Date: October 2018
  • Estimated Primary Completion Date: December 2020
  • Estimated Study Completion Date: December 2020
Arms and interventions
Arm Intervention/treatment
Active Comparator: Salt particle inhaler with content
Participants inhaling from a salt particle inhaler with content
Device: Inhalation from a salt particle inhaler with or without content
Inhalation from inhaler with (active) or without (placebo) content
Placebo Comparator: Salt particle inhaler without content
Participants inhaling from a salt particle inhaler without content
Device: Inhalation from a salt particle inhaler with or without content
Inhalation from inhaler with (active) or without (placebo) content
Outcome Measures
  • Primary Outcome Measures: 1. Muco-ciliary clearance [ Time Frame: Activity at time zero ]
    Retention of inhaled radioactive marker in percentage
  • 2. Muco-ciliary clearance [ Time Frame: Activity at time 30 minutes ]
    Retention of inhaled radioactive marker in percentage
  • 3. Muco-ciliary clearance [ Time Frame: Activity at time 90 minutes ]
    Retention of inhaled radioactive marker in percentage
  • 4. Muco-ciliary clearance [ Time Frame: Activity at time 120 minutes ]
    Retention of inhaled radioactive marker in percentage
  • Secondary Outcome Measures: 1. Registering number of coughs [ Time Frame: Activity at any time between time zero and 120 minutes ]
    Number of coughs during investigation is noted
  • 2. Collection of sputum [ Time Frame: Activity at any time between time zero and 120 minutes ]
    Sputum during investigation is collected for analysis of radioactivity content
  • 3. Symptoms in the subjects health [ Time Frame: Activity at time zero ]
    Subjective symptom description during last 24 hours is done by a CCQ (Clinical COPD Questionnaire)
  • 4. Symptoms in the subjects health [ Time Frame: Activity at time 30 ]
    Subjective symptom description during investigation is done by a questionnaire
  • 5. Symptoms in the subjects health [ Time Frame: Activity at time 120 ]
    Subjective symptom description during investigation is done by a questionnaire
Eligibility Criteria
  • Ages Eligible for Study: (Child, Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- COPD grade 1, 2 and 3 in stable condition (less than 10% change of FEV1 ratio between
investigation visits

Exclusion Criteria:

- Pregnant or lactating women

- Patients exposed to radionuclear isotopes within one month

- Patients under antibiotic treatment

- Patients with known hyper reactive airways

Contacts and Locations
Contacts

Contact: Jann Mortensen, MD Professor +45 3545 4011 Jann.Mortensen@regionh.dk

Contact: Zainab Saraj, Cand.Pharm +45 22 26 88 65 zs@liitacare.com

Locations

Denmark
Rigshospitalet, Clin nuclear and physiolog dept.
Copenhagen

Sponsors and Collaborators

Liita Care ApS

Investigators

Principal Investigator: Jann Mortensen, MD Professor Rigshospitalet, Clin Nuclear & Physiolog dept.

More Information
  • Responsible Party: Liita Care ApS
  • ClinicalTrials.gov Identifier: NCT03927365 History of Changes
  • Other Study ID Numbers: LC.001
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: February 21, 2020
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Bronchitis